ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer
- PMID: 35491008
- DOI: 10.1016/j.annonc.2022.04.009
ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer
Keywords: anaplastic thyroid cancer; follicular thyroid cancer; medullary thyroid cancer; papillary thyroid cancer; targeted therapy.
Conflict of interest statement
Disclosure CD has reported advisory boards for Eisai and Eli Lilly; DMH has received honoraria from Medtronic; SL has reported honoraria for advisory boards for Eisai, Lilly and Bayer and invited speaker for Eisai; LDL has reported advisory boards for MSD, Merck Serono and Eli Lilly and invited speaker for Eisai and consulting activity for Ipsen; KN has received honoraria as invited speaker from Eisai and nonremunerated advisory role for Ipsen; MGP has reported honoraria for advisory board for Eli Lilly and invited speaker for Roche; AB has received honoraria for advisory boards for Amgen, Astellas and Janssen, invited speaker for Amgen and institutional research funding from Astellas and Janssen; SF has declared no conflicts of interest.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
